ERBB2/HOXB13 Co-amplification with Interstitial Loss of BRCA1 Defines a Unique Subset of Breast Cancers

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39695741

Authors

Irene Rin Mitsiades

Maristela Onozato

A John Iafrate

Daniel Hicks

Doga C Gulhan

Dennis C Sgroi

Esther Rheinbay

Affiliations

Soon will be listed here.

Abstract

Background: The HOXB13/IL17RB gene expression biomarker has been shown to predict response to adjuvant and extended endocrine therapy in patients with early-stage ER+ HER2- breast tumors. HOXB13 gene expression is the primary determinant driving the prognostic and endocrine treatment-predictive performance of the biomarker. Currently, there is limited data on HOXB13 expression in HER2+ and ER- breast cancers. Herein, we studied the expression of HOXB13 in large cohorts of HER2+ and ER- breast cancers.

Methods: We investigated gene expression, genomic copy number, mutational signatures, and clinical outcome data in the TGGA and METABRIC breast cancer cohorts. Genomic-based gene amplification data was validated with tri-colored fluorescence in situ hybridization.

Results: In the TCGA breast cancer cohort, HOXB13 gene expression was significantly higher in HER2+ versus HER2- breast cancers, and its expression was also significantly higher in the ER- versus ER+ breast cancers. HOXB13 is frequently co-gained or co-amplified with ERBB2. Joint copy gains of HOXB13 and ERBB2 occurred with low-level co-gains or high-level co-amplifications (co-amp), the latter of which is associated with an interstitial loss that includes the tumor suppressor BRCA1. ERBB2/HOXB13 co-amp tumors with interstitial BRCA1 loss exhibit a mutational signature associated with APOBEC deaminase activity and copy number signatures associated with chromothripsis and genomic instability. Among ERBB2-amplified tumors of different tissue origins, ERBB2/HOXB13 co-amp with a BRCA1 loss appeared to be enriched in breast cancer compared to other tumor types. Lastly, patients with ERBB2/HOXB13 co-amplified and BRCA1 lost tumors displayed a significantly shorter progression-free survival (PFS) than those with ERBB2-only amplifications. The difference in PFS was restricted to the ER- subset patients and this difference in PFS was not solely driven by HOXB13 gene expression.

Conclusions: HOXB13 is frequently co-gained with ERBB2 at both low-copy number level or as complex high-level amplification with relative BRCA1 loss. ERBB2/HOXB13 amplified, BRCA1-lost tumors are strongly enriched in breast cancer, and patients with such breast tumors experience a shortened PFS.

References

Brechka H, Bhanvadia R, VanOpstall C, Vander Griend D . HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions. Genes Dis. 2017; 4(2):75-87. PMC: 5548135. DOI: 10.1016/j.gendis.2017.01.003. View

Taylor A, Shih J, Ha G, Gao G, Zhang X, Berger A . Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018; 33(4):676-689.e3. PMC: 6028190. DOI: 10.1016/j.ccell.2018.03.007. View

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020; 38(12):1346-1366. DOI: 10.1200/JCO.19.02309. View

Hung Y, Ueda M, Terai Y, Kumagai K, Ueki K, Kanda K . Homeobox gene expression and mutation in cervical carcinoma cells. Cancer Sci. 2003; 94(5):437-41. PMC: 11160166. DOI: 10.1111/j.1349-7006.2003.tb01461.x. View

Lopez R, Garrido E, Vazquez G, Pina P, Perez C, Alvarado I . A subgroup of HOX Abd-B gene is differentially expressed in cervical cancer. Int J Gynecol Cancer. 2006; 16(3):1289-96. DOI: 10.1111/j.1525-1438.2006.00603.x. View

Montaser R, Coley H . Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance. Cancers (Basel). 2018; 10(6). PMC: 6025235. DOI: 10.3390/cancers10060209. View

Inaki K, Menghi F, Woo X, Wagner J, Jacques P, Lee Y . Systems consequences of amplicon formation in human breast cancer. Genome Res. 2014; 24(10):1559-71. PMC: 4199368. DOI: 10.1101/gr.164871.113. View

Schiff R, Massarweh S, Shou J, Bharwani L, Arpino G, Rimawi M . Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005; 56 Suppl 1:10-20. DOI: 10.1007/s00280-005-0108-2. View

Kurokawa H, Lenferink A, Simpson J, Pisacane P, Sliwkowski M, Forbes J . Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000; 60(20):5887-94. View

10.

Gulhan D, Lee J, Melloni G, Cortes-Ciriano I, Park P . Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat Genet. 2019; 51(5):912-919. DOI: 10.1038/s41588-019-0390-2. View

11.

Curtis C, Shah S, Chin S, Turashvili G, Rueda O, Dunning M . The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403):346-52. PMC: 3440846. DOI: 10.1038/nature10983. View

12.

Abate-Shen C . Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer. 2002; 2(10):777-85. DOI: 10.1038/nrc907. View

13.

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

14.

Montemurro F, Di Cosimo S, Arpino G . Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013; 24(11):2715-24. DOI: 10.1093/annonc/mdt287. View

15.

Huang L, Pu Y, Hepps D, Danielpour D, Prins G . Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology. 2006; 148(3):1235-45. PMC: 2276874. DOI: 10.1210/en.2006-1250. View

16.

Roberts S, Lawrence M, Klimczak L, Grimm S, Fargo D, Stojanov P . An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45(9):970-6. PMC: 3789062. DOI: 10.1038/ng.2702. View

17.

Arpino G, Wiechmann L, Osborne C, Schiff R . Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008; 29(2):217-33. PMC: 2528847. DOI: 10.1210/er.2006-0045. View

18.

Cerda-Esteban N, Spagnoli F . Glimpse into Hox and tale regulation of cell differentiation and reprogramming. Dev Dyn. 2013; 243(1):76-87. DOI: 10.1002/dvdy.24075. View

19.

Yamashita T, Tazawa S, Yawei Z, Katayama H, Kato Y, Nishiwaki K . Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. Int J Oncol. 2006; 28(4):931-8. View

20.

Li Y, Roberts N, Wala J, Shapira O, Schumacher S, Kumar K . Patterns of somatic structural variation in human cancer genomes. Nature. 2020; 578(7793):112-121. PMC: 7025897. DOI: 10.1038/s41586-019-1913-9. View